What is Roth Capital’s Forecast for Biofrontera Q2 Earnings?

Biofrontera Inc. (NASDAQ:BFRI) – Investment analysts at Roth Capital issued their Q2 2025 earnings per share estimates for Biofrontera in a report issued on Thursday, November 14th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings of ($0.32) per share for the quarter. The consensus estimate for Biofrontera’s current full-year earnings is ($3.11) per share. Roth Capital also issued estimates for Biofrontera’s Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at $0.12 EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.34 EPS and FY2028 earnings at $0.63 EPS.

Separately, Benchmark reissued a “buy” rating and issued a $7.00 price objective on shares of Biofrontera in a report on Friday, November 15th.

Biofrontera Stock Up 14.4 %

BFRI stock opened at $0.77 on Monday. The company has a market cap of $4.26 million, a price-to-earnings ratio of -0.30 and a beta of 0.50. Biofrontera has a twelve month low of $0.61 and a twelve month high of $4.04. The business has a 50 day moving average price of $1.01 and a two-hundred day moving average price of $1.07.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.